About Us
About Us
Formulation science that enables tomorrow’s biologics
Formulation science that enables tomorrow’s biologics
From data-science-driven formulation selection and screening to predictive analysis, we turn antibodies, viral vectors and other ATMPs into robust drug products.
From AI-guided excipient prediction over formulation development to predictive stability modeling, we turn antibodies, viruses and viral vectors and other complex ATMPs into stable products. Please also change this in Michael´s quote on our mission on that website


About Us
About Us
Relentless about stability & speed
Relentless about stability & speed
Every molecule is different. That’s why our cross-functional labs design data-driven formulations tuned to your specific biologic and CMC timeline.
Every molecule is different. That’s why our cross-functional labs design data-driven formulations tuned to your specific biologic and CMC timeline.
Molecular modeling and excipient prediction
Formulation development using screening and optimization DoEs
Shelf life prediction




We’re bringing a data-driven mindset to formulation science by combining deep biologics expertise with advanced data science. This allows for de-risking and accelerating the development of robust, scalable drug products.

Michael Scholl
CEO
Executive Board
Executive Board
Steering vision, strategy and day-to-day execution.
Seasoned life-science entrepreneurs and biopharma leaders who chart Leukocare’s strategy, culture, and operational excellence.
Supervisory Board
Independent governance and strategic guidance.
Independent industry veterans and investment leaders providing governance, capital-market insight, and long-term strategic direction.
Scientific Advisory Board
World-class scientists who keep our innovation edge sharp.
Globally renowned scientists who channel the latest academic breakthroughs into our formulation technologies and R&D pipeline.
Interested in Molecular Modeling to understand the cQAs of your product?

Interested in fill and finish services for non-clinical tox studies?

Latest Publications
Oct 12, 2022
Efficient stabilization of therapeutic hepatitis B vaccine components by amino-acid formulation maintains its potential to break immune tolerance
JHEP Reports. 2023 Feb; 5(2): 100603
SACHERL J. ET AL: Efficient stabilization of therapeutic hepatitis B vaccine components by amino-acid formulation maintains its potential to break immune tolerance
Nov 9, 2018
Rentschler Biopharma SE / LEUKOCARE AG/ Informa Pharma Intelligence
Rentschler Biopharma SE / LEUKOCARE AG/ Informa Pharma Intelligence
"2018 Survey- Formulation in the Drug Product Development Process": 2018 Survey ‘Formulation in the Drug Product Development Process’, based on research from Informa Pharma Intelligence
Apr 20, 2010
Oct 12, 2022
Efficient stabilization of therapeutic hepatitis B vaccine components by amino-acid formulation maintains its potential to break immune tolerance
JHEP Reports. 2023 Feb; 5(2): 100603
SACHERL J. ET AL: Efficient stabilization of therapeutic hepatitis B vaccine components by amino-acid formulation maintains its potential to break immune tolerance
Nov 9, 2018
Rentschler Biopharma SE / LEUKOCARE AG/ Informa Pharma Intelligence
Rentschler Biopharma SE / LEUKOCARE AG/ Informa Pharma Intelligence
"2018 Survey- Formulation in the Drug Product Development Process": 2018 Survey ‘Formulation in the Drug Product Development Process’, based on research from Informa Pharma Intelligence
Apr 20, 2010
Oct 12, 2022
Efficient stabilization of therapeutic hepatitis B vaccine components by amino-acid formulation maintains its potential to break immune tolerance
JHEP Reports. 2023 Feb; 5(2): 100603
SACHERL J. ET AL: Efficient stabilization of therapeutic hepatitis B vaccine components by amino-acid formulation maintains its potential to break immune tolerance
Nov 9, 2018
Rentschler Biopharma SE / LEUKOCARE AG/ Informa Pharma Intelligence
Rentschler Biopharma SE / LEUKOCARE AG/ Informa Pharma Intelligence
"2018 Survey- Formulation in the Drug Product Development Process": 2018 Survey ‘Formulation in the Drug Product Development Process’, based on research from Informa Pharma Intelligence
Apr 20, 2010